Mariana Brandão

Dr. Mariana Brandão

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MBMariana Brandão
Mariana Brandão
RBRiccardo Bariani
Riccardo Bariani
IRIlaria Rigato
Ilaria Rigato
BBBarbara Bauce
Barbara Bauce
Desmoplakin (DSP) is a desmosomal protein that plays an essential role for cell-to-cell adhesion within the cardiomyocytes. The first association between DSP genetic variants and the presence of a myocardial disease referred to patients with Carvajal syndrome. Since then, several reports have linked the DSP gene to familial forms of arrhythmogenic (ACM) and dilated cardiomyopathies. Left-dominant ACM is the most common phenotype in individuals carrying DSP variants. More recently, a new entity—“Desmoplakin cardiomyopathy”—was described as a distinct form of cardiomyopathy characterized by frequent left ventricular involvement with extensive fibrosis, high arrhythmic risk, and episodes of acute myocardial injury. The purpose of this review was to summarize the available evidence on DSP cardiomyopathy and to identify existing gaps in knowledge that need clarification from upcoming research.

29 July 2022 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
PGPedro Gonçalves-Teixeira
Pedro Gonçalves-Teixeira
TCTelma Costa
Telma Costa
IFIsabel Fragoso
Isabel Fragoso
DFDiogo Ferreira
Diogo Ferreira
MBMariana Brandão
Mariana Brandão
RFRicardo Fontes-Carvalho
Ricardo Fontes-Carvalho
Resumo A fibrilação atrial (FA) é a arritmia cardíaca sustentada mais comum na população geral, tendo uma alta carga de morbimortalidade, e isso também é válido para pacientes com câncer. A associação entre FA e câncer vai ainda mais longe, com alguns estudos sugerindo que a FA pode ser um marcador de câncer oculto. Há, no entanto, uma notável escassez de dados sobre os desafios específicos do manejo da FA em pacientes com câncer. O reconhecimento e o manejo imediatos [...] Resumo A fibrilação atrial (FA) é a arritmia cardíaca sustentada mais comum na população geral, tendo uma alta carga de morbimortalidade, e isso também é válido para pacientes com câncer. A associação entre FA e câncer vai ainda mais longe, com alguns estudos sugerindo que a FA pode ser um marcador de câncer oculto. Há, no entanto, uma notável escassez de dados sobre os desafios específicos do manejo da FA em pacientes com câncer. O reconhecimento e o manejo imediatos

17 December 2021 in Heart Rhythm O2
Verified
Journal Article
Open access
MBMariana Brandão
Mariana Brandão
JAJoão Gonçalves Almeida
João Gonçalves Almeida
PFPaulo Fonseca
Paulo Fonseca
JMJoel Monteiro
Joel Monteiro
ESElisabeth Santos
Elisabeth Santos
RFRicardo Fontes-Carvalho
Ricardo Fontes-Carvalho
Upgrade to cardiac resynchronization therapy (CRT) is common in Europe, despite little and conflicting evidence. To compare long-term clinical outcomes in a cohort of patients receiving de novo or upgrade to CRT. Single-center retrospective study of 295 consecutive patients submitted to CRT implantation between 2007 and 2018. Upgraded and de novo patients complying with a dedicated follow-up protocol were compared in terms of clinical (NYHA class improvement without major adverse cardiac events [MACE] in the first year of follow-up) and echocardiographic (left ventricle end-systolic volume reduction of >15% during the first year) response. No differences in the rate of clinical (59.3% vs 62.6%, P = .765) or echocardiographic response (72.2% vs 71.9%, P = .970) between groups were observed. Device-related complications were also comparable between groups (8.9% vs 8.4%, P = .892). Occurrence of MACE and all-cause mortality were analyzed over a median follow-up of 3 (interquartile range 1–6) years: MACE occurred less frequently in the de novo group (hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.34–0.90, P = .018), but all-cause mortality was similar among groups (HR: 0.87, 95% CI: 0.46–1.64, P = .684). Propensity score–matching analysis was performed to adjust for possible confounder variables. In the propensity-matched samples, all-cause mortality (HR: 1.26, 95% CI: 0.56–2.77, P = .557) and MACE (HR: 0.84, 95% CI: 0.46–1.54, P = .574) were comparable between upgrade and de novo patients. Survival after upgrade to resynchronization therapy was comparable to de novo implants. Additionally, clinical and echocardiographic response to CRT in upgraded patients were similar to de novo patients.

6 May 2021 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Closed access
PDF file
MBMariana Brandão
Mariana Brandão
PGPedro Gonçalves-Teixeira
Pedro Gonçalves-Teixeira
PQPedro Ribeiro Queirós
Pedro Ribeiro Queirós
NFNuno Dias Ferreira
Nuno Dias Ferreira
MOMarco Oliveira
Marco Oliveira
Homem diabético de 65 anos com procedimento de Bentall prévio e prótese valvar aórtica mecânica apresentou febre e dor abdominal, juntamente com sopro sistólico (III/VI) e marcadores inflamatórios elevados. A tomografia computadorizada (TC) abdominal revelou infarto esplênico. Ecocardiograma transesofágico (ETE) foi negativo para vegetações. Diante da suspeita persistente de endocardite infecciosa (EI) com embolia periférica, iniciou-se terapia antimicrobiana empírica. Posteriormente, o paciente apresentou bloqueio atrioventricular total, necessitando de estimulação transvenosa temporária. Posteriormente, implantou-se um marca-passo epicárdico. Na ocasião, a TC [...] Homem diabético de 65 anos com procedimento de Bentall prévio e prótese valvar aórtica mecânica apresentou febre e dor abdominal, juntamente com sopro sistólico (III/VI) e marcadores inflamatórios elevados. A tomografia computadorizada (TC) abdominal revelou infarto esplênico. Ecocardiograma transesofágico (ETE) foi negativo para vegetações. Diante da suspeita persistente de endocardite infecciosa (EI) com embolia periférica, iniciou-se terapia antimicrobiana empírica. Posteriormente, o paciente apresentou bloqueio atrioventricular total, necessitando de estimulação transvenosa temporária. Posteriormente, implantou-se um marca-passo epicárdico. Na ocasião, a TC

5 May 2026 in Circulation
Verified
Journal Article
Open access
BPBelén Peiró-Aventín
Belén Peiró-Aventín
ERElena Revuelta-López
Elena Revuelta-López
MBMariana Brandão
Mariana Brandão
JNJulio Núñez
Julio Núñez
MFManuel Fernandez-Rojo
Manuel Fernandez-Rojo
PGPablo García-Pavía
Pablo García-Pavía
BACKGROUND: With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new therapies, there is a rising demand for tools to stratify risk and prognosis. We evaluated the prognostic value of multiple circulating biomarkers for predicting outcomes in ATTR-CM. METHODS: We evaluated 12 different circulating biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP], high-sensitivity troponin I [hsTnI], mid-regional pro-adrenomedullin [MR-proADM], carbohydrate antigen 125 [CA125], soluble suppression of tumorigenicity 2 [sST2], cluster of differentiation antigen 146 [CD146], growth/differentiation factor-15 [GDF-15], alpha-klotho, fibroblast growth factor 23 [FGF-23], galectin-3, insulin-like growth factor-binding protein 7 [IGFBP-7], and estimated glomerular filtration rate [eGFR]) in 337 ATTR-CM patients from Spain. Cox models were employed to determine their predictive abilities. Findings were validated in 2 independent external cohorts of 210 patients from the United States and 416 patients from the ATTR-ACT trial, respectively. RESULTS: Over a median follow-up of 19.7 months (IQR, 6.5–42.3), 67 patients (19.9%) died/underwent heart transplantation, and 81 (24%) had heart failure events. MR-proADM was the biomarker with the strongest prognostic performance, with a C-index of 0.788 (95% CI, 0.723–0.851) for all-cause mortality and 0.721 (95% CI, 0.669–0.772) for the composite end point of death and heart failure events. MR-proADM was associated with multiple parameters of ATTR-CM severity and was independently associated with mortality, heart failure events, and the composite end point. MR-proADM ≥1.1 nmol/L was identified as the optimal prognostic threshold, and it improved prediction of mortality when added to the National Amyloid Center (area under the curve [AUC], 0.682 versus 0.737; P <0.001), Mayo (AUC, 0.659 versus 0.749; P <0.001), and the Columbia staging systems (AUC, 0.699 versus 0.768; P <0.001). In both validation cohorts, patients with MR-proADM ≥1.1 nmol/L had worse outcomes ( P <0.001). This association was also confirmed in patients receiving tafamidis. CONCLUSIONS: In patients with ATTR-CM, MR-proADM levels are associated with disease severity and worse prognosis. MR-proADM improves prediction of all-cause mortality and captures heart failure events.

2 March 2022 in Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
PQPedro Ribeiro Queirós
Pedro Ribeiro Queirós
MSMariana Ribeiro Silva
Mariana Ribeiro Silva
GSGualter Santos Silva
Gualter Santos Silva
MBMariana Brandão
Mariana Brandão
NDNuno Dias-Ferreira
Nuno Dias-Ferreira
Ribeiro Queirós P, et al. J Cardiovasc Imaging. 2022 Mar;30:e18. https://doi.org/10.4250/jcvi.2021.0198